188 related articles for article (PubMed ID: 35900839)
1. miR-3156-5p is downregulated in serum of MEN1 patients and regulates expression of MORF4L2.
Kooblall KG; Stokes VJ; Shariq OA; English KA; Stevenson M; Broxholme J; Wright B; Lockstone HE; Buck D; Grozinsky-Glasberg S; Yates CJ; Thakker RV; Lines KE
Endocr Relat Cancer; 2022 Oct; 29(10):557-568. PubMed ID: 35900839
[TBL] [Abstract][Full Text] [Related]
2. [Plasma miRNA expression in patients with genetically confirmed multiple endocrine neoplasia type 1 syndrome and its phenocopies].
Trukhina DA; Mamedova EO; Nikitin AG; Koshkin PA; Belaya ZE; Melnichenko GA
Probl Endokrinol (Mosk); 2024 Jan; 69(6):70-85. PubMed ID: 38311997
[TBL] [Abstract][Full Text] [Related]
3. MiR-15a/miR-16-1 expression inversely correlates with cyclin D1 levels in Men1 pituitary NETs.
Lines KE; Newey PJ; Yates CJ; Stevenson M; Dyar R; Walls GV; Bowl MR; Thakker RV
J Endocrinol; 2018 Sep; 240(1):41-50. PubMed ID: 30389902
[TBL] [Abstract][Full Text] [Related]
4. Role of miR-24 in Multiple Endocrine Neoplasia Type 1: A Potential Target for Molecular Therapy.
Marini F; Brandi ML
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298972
[TBL] [Abstract][Full Text] [Related]
5. Thoracic and duodenopancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1: natural history and function of menin in tumorigenesis.
Pieterman CR; Conemans EB; Dreijerink KM; de Laat JM; Timmers HT; Vriens MR; Valk GD
Endocr Relat Cancer; 2014 Jun; 21(3):R121-42. PubMed ID: 24389729
[TBL] [Abstract][Full Text] [Related]
6. MEN1 mutations and potentially MEN1-targeting miRNAs are responsible for menin deficiency in sporadic and MEN1 syndrome-associated primary hyperparathyroidism.
Grolmusz VK; Borka K; Kövesdi A; Németh K; Balogh K; Dékány C; Kiss A; Szentpéteri A; Sármán B; Somogyi A; Csajbók É; Valkusz Z; Tóth M; Igaz P; Rácz K; Patócs A
Virchows Arch; 2017 Sep; 471(3):401-411. PubMed ID: 28597079
[TBL] [Abstract][Full Text] [Related]
7. Multiple Endocrine Neoplasia Type 1 (MEN1) 5'UTR Deletion, in MEN1 Family, Decreases Menin Expression.
Kooblall KG; Boon H; Cranston T; Stevenson M; Pagnamenta AT; Rogers A; Grozinsky-Glasberg S; Richardson T; Flanagan DE; ; Taylor JC; Lines KE; Thakker RV
J Bone Miner Res; 2021 Jan; 36(1):100-109. PubMed ID: 32780883
[TBL] [Abstract][Full Text] [Related]
8. Multiple endocrine neoplasia type 1 knockout mice develop parathyroid, pancreatic, pituitary and adrenal tumours with hypercalcaemia, hypophosphataemia and hypercorticosteronaemia.
Harding B; Lemos MC; Reed AA; Walls GV; Jeyabalan J; Bowl MR; Tateossian H; Sullivan N; Hough T; Fraser WD; Ansorge O; Cheeseman MT; Thakker RV
Endocr Relat Cancer; 2009 Dec; 16(4):1313-27. PubMed ID: 19620250
[TBL] [Abstract][Full Text] [Related]
9. Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4).
Thakker RV
Mol Cell Endocrinol; 2014 Apr; 386(1-2):2-15. PubMed ID: 23933118
[TBL] [Abstract][Full Text] [Related]
10. Clinically Defined Mutations in
Duan S; Sheriff S; Elvis-Offiah UB; Witten BL; Sawyer TW; Sundaresan S; Cierpicki T; Grembecka J; Merchant JL
Cancer Res Commun; 2023 Jul; 3(7):1318-1334. PubMed ID: 37492626
[TBL] [Abstract][Full Text] [Related]
11. Multiple endocrine neoplasia type 1: extensive analysis of a large database of Florentine patients.
Marini F; Giusti F; Brandi ML
Orphanet J Rare Dis; 2018 Nov; 13(1):205. PubMed ID: 30428914
[TBL] [Abstract][Full Text] [Related]
12. Clinical studies of multiple endocrine neoplasia type 1 (MEN1).
Trump D; Farren B; Wooding C; Pang JT; Besser GM; Buchanan KD; Edwards CR; Heath DA; Jackson CE; Jansen S; Lips K; Monson JP; O'Halloran D; Sampson J; Shalet SM; Wheeler MH; Zink A; Thakker RV
QJM; 1996 Sep; 89(9):653-69. PubMed ID: 8917740
[TBL] [Abstract][Full Text] [Related]
13. Increased menin expression in sporadic pituitary adenomas.
Wrocklage C; Gold H; Hackl W; Buchfelder M; Fahlbusch R; Paulus W
Clin Endocrinol (Oxf); 2002 May; 56(5):589-94. PubMed ID: 12030908
[TBL] [Abstract][Full Text] [Related]
14. An autoregulatory network between menin and pri-miR-24-1 is required for the processing of its specific modulator miR-24-1 in BON1 cells.
Luzi E; Marini F; Ciuffi S; Galli G; Brandi ML
Mol Biosyst; 2016 May; 12(6):1922-8. PubMed ID: 27098433
[TBL] [Abstract][Full Text] [Related]
15. Clinical Profile and Mutations Associated with Multiple Endocrine Neoplasia-Type1 (MEN1) and Their First-Degree Relatives at Risk of Developing MEN1: A Prospective Study.
Shyamasunder AH; Pai R; Ramamoorthy H; Sakhti D; Manipadam MT; Kapoor N; Paul TV; Jebasingh F; Thomas N; Abraham DT; Paul MJ; Chacko AG; Prabhu K; Rajaratnam S
Horm Metab Res; 2021 Apr; 53(4):245-256. PubMed ID: 33853118
[TBL] [Abstract][Full Text] [Related]
16. Pancreatic Neuroendocrine Neoplasms in Multiple Endocrine Neoplasia Type 1.
Marini F; Giusti F; Tonelli F; Brandi ML
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33919851
[TBL] [Abstract][Full Text] [Related]
17. A MEN1 pancreatic neuroendocrine tumour mouse model under temporal control.
Lines KE; Vas Nunes RP; Frost M; Yates CJ; Stevenson M; Thakker RV
Endocr Connect; 2017 May; 6(4):232-242. PubMed ID: 28420716
[TBL] [Abstract][Full Text] [Related]
18. Multiple endocrine neoplasia type 1 (MEN1).
Thakker RV
Best Pract Res Clin Endocrinol Metab; 2010 Jun; 24(3):355-70. PubMed ID: 20833329
[TBL] [Abstract][Full Text] [Related]
19. Multiple endocrine neoplasia type 1.
Marini F; Falchetti A; Del Monte F; Carbonell Sala S; Gozzini A; Luzi E; Brandi ML
Orphanet J Rare Dis; 2006 Oct; 1():38. PubMed ID: 17014705
[TBL] [Abstract][Full Text] [Related]
20. 10 Swiss kindreds with multiple endocrine neoplasia type 1: assessment of screening methods.
Clerici T; Schmid C; Komminoth P; Lange J; Spinas GA; Brändle M
Swiss Med Wkly; 2001 Jun; 131(25-26):381-6. PubMed ID: 11524904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
